14 July 2026
July BNF + BNFC Knowledge Updates
British National Formulary
This update contains 7 significant changes and 2 new monographs.
Significant changes
Antibacterials, principles of therapy: updated guidance on notifiable diseases.
Dutasteride: updated safety warnings for psychiatric side effects and sexual dysfunction [MHRA/CHM advice].
Fenofibrate: new indication and dose for non-proliferative diabetic retinopathy in type 2 diabetes mellitus.
Finasteride: updated safety warnings for psychiatric side effects and sexual dysfunction [MHRA/CHM advice].
Hyperkalaemia: updated guidance on management of mild to moderate hyperkalaemia.
Xylometazoline hydrochloride: Nasal decongestant sprays and drops containing xylometazoline hydrochloride / oxymetazoline hydrochloride: increased risk of rebound congestion, rhinitis medicamentosa, and tachyphylaxis with overuse [MHRA/CHM advice].
Xylometazoline hydrochloride: update to maximum duration of use for nasal congestion.
New monographs
Loqtorzi® [toripalimab] for Oesophageal squamous cell carcinoma, Nasopharyngeal carcinoma.
Lynkuet® [elinzanetant] for Moderate to severe vasomotor symptoms associated with menopause.
BNF for Children
This update contains 4 significant changes.
Significant changes
Antibacterials, principles of therapy: updated guidance on notifiable diseases.
Ceftriaxone: new indication and dose for sepsis.
Xylometazoline hydrochloride: Nasal decongestant sprays and drops containing xylometazoline hydrochloride/oxymetazoline hydrochloride: increased risk of rebound congestion, rhinitis medicamentosa, and tachyphylaxis with overuse [MHRA/CHM advice].
Xylometazoline hydrochloride: update to maximum duration of use for nasal congestion.
